FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a pharmaceutical composition used for treating or preventing a cardiovascular disease in an individual in need thereof and containing at least 95% ethyleicosapentaenoate (ethyl-EPA) encased in a capsule containing gelatine, glycerol, sorbitol, maltitol and purified water, wherein the composition has an initial peroxide number of no more than 5 mEq/kg and the second peroxide number of no more than 8 mEq/kg if stored at 25°C and relative humidity (RH) of 60% for 6 months.
EFFECT: invention refers to a method of treating or preventing the cardiovascular diseases involving administering a therapeutically effective amount of this composition into the individual in need thereof.
18 cl, 4 ex, 4 tbl, 3 dwg
